Company: RPTX
Filing Date: 2025-11-17
Form Type: DEFA14A
Source: 0001193125-25-284040
Chunk: 21

Company: Repare Therapeutics Inc.
Filing Date: 2025-11-17
Form: DEFA14A
Chunk 21
---
ary shall not include any amounts otherwise deducted from Closing Net Cash pursuant to Section 1.1(z). |

| (aaaa) | “Material Adverse Change” means any fact or state of facts, circumstance, change, effect,                                                                                                                                                
 occurrence or event that (i) either individually or in the aggregate prevents or materially delays, or individually or in the aggregate would reasonably be expected to prevent or materially delay the consummation of the Contemplated 
 Transaction; or (ii) individually or in the aggregate is, or would reasonably be expected to be, material and adverse to the financial condition, assets or liabilities (contingent or otherwise) of the Company and its Subsidiary,     |

- 8 -

| taken as a whole, other than any such change, effect, occurrence or event directly or indirectly relating to or resulting from: |

| (A) | conditions generally affecting the industries in which the Company and its Subsidiary operate in jurisdictions 
 in which the Company and its Subsidiary carry on business;                                                     |

| (B) | changes to applicable Laws, GAAP or changes in accounting or regulatory requirements generally applicable to 
 the industries in which such Party and its Subsidiary operate as a whole;                                    |

| (C) | changes to the general economic, financial, currency exchange, securities or commodity market conditions in 
 Canada or the United States or elsewhere;                                                                   |

| (D) | changes to the global, national or regional political conditions, including the outbreak of war or acts of 
 terrorism;                                                                                                 |

| (E) | any hurricane, flood, tornado, earthquake or other natural disaster, epidemic, pandemic or disease outbreak, or 
 any material worsening of such conditions existing as of the date of this Agreement;                            |

| (F) | relating to a change in the market trading price or trading volume of the Company’s publicly listed                                                                                                                      
 securities (it being understood that, unless otherwise excluded by (A) through (K) inclusively, the causes underlying any such change may be considered to determine whether same constitute a Material Adverse Change); |

| (G) | the failure of the Company to meet any internal or published projections, forecasts or estimates of revenues,                                                                                                                                
 earnings or cash flow (it being understood that, unless otherwise excluded by Sections (A) through (K) inclusively, the causes underlying any such change may be considered to determine whether same constitute a Material Adverse Change); |

| (H) | the announcement of this